Inflammatory Demyelinating Polyneuropathy
📧 Sign up to get email alerts when something new happens for Inflammatory Demyelinating Polyneuropathy.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-02-11EMA Authorised: HyQvia (human normal immunoglobulin) — Baxalta Innovations GmbH
EMA authorised HyQvia, a subcutaneous immunoglobulin product with recombinant human hyaluronidase, from Baxalta Innovations GmbH for immunod…
-
EMA approval · 2026-01-23EMA Authorised: Vyvgart (efgartigimod alfa) — Argenx
The European Medicines Agency has authorised Vyvgart (efgartigimod alfa) for the treatment of myasthenia gravis and chronic inflammatory dem…
-
EMA approval · 2025-05-16EMA Authorised: Deqsiga (human normal immunoglobulin) — Takeda Manufacturing Austria AG
EMA authorised Deqsiga, a human normal immunoglobulin product from Takeda Manufacturing Austria AG, for several immunologic and neuropathic …